Moffitt Cancer Center

Within polycythemia vera, patients can be iron deficient while continuing to produce too many red blood cells, explains Andrew Kuykendall, MD.

Andrew Kuykendall, MD, lead investigator for the VERIFY trial supporting the approval, said rusfertide is used to treat erythrocytosis in polycythemia vera.

In this Director’s Cut episode of Managed Care Cast, we speak with Surbhi Sidana, MD, Stanford University, on the transformation of the myeloma field.

FDA approves rusfertide, a first-in-class hepcidin-mimetic for polycythemia vera, cutting phlebotomies and improving hematocrit control and QOL.

Doris Hansen, MD, co-led "Bridging the Gaps in Health Equity and Access in Multiple Myeloma" on May 2, 2026, in Tampa, Florida.

New research reveals ruxolitinib’s hidden cholesterol risk in patients who have MPN and pelabresib’s durable benefit when added to ruxolitinib in myelofibrosis.

Although they covered diverse topics across the cancer continuum, the event’s 4 panel discussions shared a common focus on advancing more equitable and coordinated care.

Kathrin Dvir, MD, MSc, concludes by highlighting the importance of outreach, education, and trusted messaging to improve breast cancer screening adherence.

Kathrin Dvir, MD, MSc, discusses how biomarker-driven care, targeted therapies, and evolving sequencing are shaping modern breast cancer treatment.

As more oral cancer therapies become available, medically integrated dispensing models are increasingly vital, says Kenneth Komorny, PharmD, BCPS.

Susan Vadaparampil, PhD, MPH, explains that aligning clinical trials with community needs can improve enrollment diversity.

Medically integrated dispensing (MID) models help build patient trust in pharmacists, which can help improve adherence, explains Kenneth Komorny, PharmD, BCPS.

Patient navigators, community health workers, and/or peer advocates serve as trusted community resources for patients, Susan Vadaparampil, PhD, MPH, says.

Medically integrated dispensing is well-positioned to support value-based oncology care models and closer patient follow-up and monitoring, says Katherine Tobon, PharmD, BCOP.

MID in oncology also enhances treatment adherence and improves patient outcomes, according to Kenneth Komorny, PharmD, BCPS.

Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.

Susan Vadaparampil, PhD, MPH, highlights disparities in cancer outcomes and trial enrollment but underscores that linking community screening programs with cancer centers may help.

At the Orlando session of the Institute for Value-Based Medicine, clinicians delivering cancer care in Central Florida address restrictions from Medicare Advantage plans, which can affect access to innovative treatments for breast cancer, myeloma, and bladder cancer.

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast cancer care and payer friction.

Zanubrutinib shows superior progression-free and overall survival in relapsed mantle cell lymphoma compared with acalabrutinib, according to a new analysis.

Rusfertide has received orphan drug, fast track, and breakthrough therapy designations from the FDA, and in this interview, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the critical need for therapies that offer a sense of normalcy to individuals with polycythemia vera.

Noting the profound impact of living with a chronic condition that constantly reminds patients of their "patient" status, Andrew Kuykendall, MD, Moffitt Cancer Center, emphasizes the importance of therapies that can offer a sense of normalcy.

Andrew Kuykendall, MD, Moffitt Cancer Center, explains the goals of the VERIFY trial and why its data on rusfertide could have paradigm-changing implications for patients with polycythemia vera (PV) who currently rely on frequent phlebotomies for relief.